Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of small-molecule tyrosine kinase inhibitors: Optimizing the magic bullet.

Current opinion in molecular therapeutics - 1 Dec 2010

Pander Jan, Guchelaar Henk Jan, Gelderblom Hans

Abstract excerpt

Cancer treatment has undergone revolutionary changes during the past decade, as a result of the introduction of tyrosine kinase inhibitors (TKIs) that selectively inhibit growth factor pathways critical for tumor growth. Unexpected toxicity profiles and disappointing response rates to these 'magic bullets' have prompted research to identify markers that can predict toxicity or response to such agents. This review...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily B
Share to ATP Binding Cassette Transporter, Subfamily B, Member 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ATP Binding Cassette Transporter, Subfamily G, Member 2

Share to Benzamides

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Imatinib Mesylate

Share to Quinazolines

Source

Identifiers

PMID: 21154157

Genes

EGFR
ABCB1
ABCG2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of small-molecule tyrosine kinase inhibitors: Optimizing the magic bullet.PMID 21154157Read ↗

Pharmacogenetics of EGFR and VEGF inhibition.Semantic proximity Read ↗

Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer.Semantic proximity Read ↗

Part 1: background, methodology, and clinical adoption of pharmacogenetics.Semantic proximity Read ↗

Application of genotype-guided cancer therapy in solid tumors.Semantic proximity Read ↗

Pharmacogenetics and pharmacogenomics: role of mutational analysis in anti-cancer targeted therapySemantic proximity Read ↗

Germline pharmacogenomics in oncology: decoding the patient for targeting therapy.Semantic proximity Read ↗

Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects.Semantic proximity Read ↗

Clinical pharmacogenetics in oncology: the paradigm of molecular targeted therapies.Semantic proximity Read ↗

Role of Genetic Polymorphisms in Drug-Metabolizing Enzyme-Mediated Toxicity and Pharmacokinetic Resistance to Anti-Cancer Agents: A Review on the Pharmacogenomics Aspect.Semantic proximity Read ↗

Pharmacogenomic biomarkers for personalized cancer treatment.Semantic proximity Read ↗

A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review.Semantic proximity Read ↗

The role of pharmacogenomics in metastatic renal cell carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.